意達利控股(00720.HK)認購一間生物製劑開發及製造公司A系列5184.8萬股優先股
格隆匯1月29日丨意達利控股(00720.HK)公告,於2020年1月29日,投資者B彩盈投資有限公司(公司間接全資附屬公司)及投資者AIdea View Limited(獨立第三方)與Chime Biologics、母公司、CBL香港公司、CBL武漢I及CBL武漢II訂立CBL認購協議。
於CBL重組前,CBL香港公司、CBL武漢I及CBL武漢II一直從事生物製劑合約開發及製造服務業務,併為母公司直接或間接全資附屬公司。根據CBL重組(當中包括CBL認購協議項下擬進行交易),Chime Biologics將成為CBL集團其他成員公司(將繼續進行CDMO業務)控股公司,而Chime Biologics將不再由母公司全資擁有,其於緊隨重組後將(i)由母公司現有股東以CBL普通股方式擁有;及(ii)由投資者B及投資者A以CBLA系列優先股方式擁有。
於完成時,投資者B將持有5184.8萬股CBLA系列優先股,相當於緊接完成後(i)已發行CBLA系列優先股約25.60%;及(ii)Chime Biologics經擴大已發行股本(包括CBL普通股及已轉換基準計算CBLA系列優先股)約11.82%。發行上述5184.8萬股A系列優先股代價合共為3200萬美元,而每股CBLA系列優先股認購價約為0.617美元,將由投資者B以現金繳付。於完成後,Chime Biologics將以公司聯營公司入賬,且將不會視作其附屬公司。
於CBL重組前,CBL香港公司、CBL武漢I及CBL武漢II一直進行生物製劑合約開發及製造服務業務;而其為母公司直接或間接全資附屬公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.